

COVID-19 vaccination coverage by company size and the effects of socioeconomic factors and workplace vaccination in Japan: a cohort study

Koji Mori^{1*}, Takahiro Mori¹, Tomohisa Nagata¹, Hajime Ando², Ayako Hino³, Seiichiro Tateishi⁴, Mayumi Tsuji⁵, Keiji Muramatsu⁶, Yoshihisa Fujino⁷ for the CORoNa Work Project

¹Department of Occupational Health Practice and Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

²Department of Work Systems and Health, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan

³Department of Mental Health, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

⁴Department of Occupational Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

⁵Department of Environmental Health, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

⁶Department of Preventive Medicine and Community Health, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

⁷Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

* Corresponding author: Koji Mori, kmori@med.uoeh-u.ac.jp

Short title: COVID-19 vaccination coverage by company size

Total word count: 3369 (6400 max)

1 **Abstract**

2 **Background:** Vaccination is considered the most effective control measure against
3 COVID-19. Vaccine hesitancy and equitable vaccine allocation are important challenges to
4 disseminating developed vaccines. To promote COVID-19 vaccination coverage, the
5 government of Japan established the workplace vaccination program. However, while it
6 appears that the program was effective in overcoming vaccine hesitancy, the program may
7 have hindered the equitable allocation of vaccines because it mainly focused on employees of
8 large companies. We investigated the relationship between company size and COVID-19
9 vaccination completion status of employees and the impact of the workplace vaccination
10 program on this relationship.

11 **Methods:** We conducted an internet-based prospective cohort study from December 2020
12 (baseline) to December 2021. The data were collected using a self-administered questionnaire
13 survey. Briefly, 27,036 workers completed the questionnaire at baseline and 18,560 at
14 follow-up. After excluding ineligible respondents, we finally analyzed the data from 15,829
15 participants. At baseline, the participants were asked about the size of the company they
16 worked for, and at follow-up they were asked about the month in which they received their
17 second COVID-19 vaccine dose and the availability of a company-arranged vaccination
18 opportunity.

19 **Results:** In each month throughout the observation period, the odds of having received a

20 second COVID-19 vaccine dose were significantly lower for small-company employees than
21 for large-company employees in the sex- and age-adjusted model. This difference decreased
22 after adjusting for socioeconomic factors, and there was no significant difference after
23 adjusting for the availability of a company-arranged vaccination opportunity.

24 **Conclusions:** The workplace vaccination program implemented in Japan to control the
25 COVID-19 pandemic may have been effective in overcoming vaccine hesitancy in workers;
26 however, it may have caused an inequitable allocation of vaccines between companies of
27 different sizes. Because people who worked for small companies were less likely to be
28 vaccinated, it will be necessary to enhance support of vaccination for this population in the
29 event of future infectious disease outbreaks.

30 **Trial registration:** Not applicable.

31

32 **Keywords:** COVID-19, Vaccine hesitancy, Equitable allocation, Workplace vaccination,
33 Company size, Socioeconomic factors

34

35 Introduction

36 Vaccination programs are underway worldwide because vaccination is the most effective
37 measure to control the coronavirus disease 2019 (COVID-19) pandemic, which was declared
38 by the World Health Organization (WHO) in March 2020. Since the outbreak of COVID-19
39 in China in December 2019 [1], various types of vaccines have been developed in a short
40 period of time [2]. Some of these are mRNA vaccines, representing a new type of vaccine
41 technology [3].

42 Disseminating vaccines presents many challenges, among which vaccine hesitancy
43 and equitable allocation are prominent. Vaccine hesitancy, defined as the “delay in
44 acceptance or refusal of vaccination despite the availability of vaccination services” is
45 considered a major public health challenge in infectious disease control because it delays
46 vaccination of the population and inhibits the acquisition of herd immunity [4]. Various
47 factors, including socioeconomic [5] and psychological factors [4], have been found to
48 contribute to people’s vaccine hesitancy. Such factors have also been examined in the context
49 of COVID-19 vaccination [6,7]. The equitable allocation of vaccines is based on maintaining
50 equity in the order of vaccination according to risk regardless of social status, for example by
51 starting with healthcare workers and those at higher risk of serious illness [8].

52 In Japan, the majority of the population had some level of initial vaccine hesitancy to
53 receive a COVID-19 vaccine [9,10]. Nevertheless, by the end of December 2021,

54 approximately 80% of the population had received two vaccine doses [11]. In Japan,
55 COVID-19 vaccination efforts began on February 17, 2021 using two mRNA vaccines: one
56 from Pfizer Inc. and one from Moderna Inc. In consideration of equitable vaccine allocation,
57 the vaccination of healthcare workers was followed by the vaccination of older adults [12].
58 Thereafter, vaccination progressed through the general population in stages according to age.

59 An aspect of COVID-19 vaccination in Japan has been the availability of vaccination
60 at workplaces in addition to community settings provided by municipalities and clinics [12].
61 Compared with other developed countries, the start of the vaccination program was delayed
62 in Japan. To make up for this delay, the government appointed a minister to be in charge and
63 set a goal of administering one million vaccinations per day. Part of the vaccination strategy
64 was to implement the opportunity for workplace vaccination, which was conducted mainly by
65 occupational health professionals such as occupational physicians and occupational health
66 nurses. As a result, 9,654,000 people received their second vaccine dose through the
67 workplace vaccination program, which started on June 21, 2021 [13]. Workplace vaccination,
68 which provides a convenient vaccination opportunity, may have reduced vaccine hesitancy
69 because several psychological and social factors can positively influence a person's
70 vaccination decision.

71 The workplace COVID-19 vaccination program in Japan, however, may have
72 negatively affected the equitable allocation of vaccine doses. This program primarily targeted

73 large companies, with a minimum of 2,000 doses to be delivered to a single location (i.e., an
74 expected vaccination coverage of at least 1,000 persons [13]). Thus, there were barriers to its
75 implementation in small and medium-sized companies. Therefore, company size may have
76 affected the timing and coverage of employees receiving the second COVID-19 vaccine dose.

77 We hypothesized that while the workplace vaccination program facilitated
78 COVID-19 vaccination, there was a size-dependent difference among companies in the
79 timing of employees receiving the second vaccine dose and that this difference was
80 influenced by the availability of a company-arranged vaccination opportunity. In a survey
81 conducted in Japan during the COVID-19 pandemic, there were differences in the
82 implementation of infection control measures and the opportunity to work remotely
83 depending on the size of the company [14,15]. Disparities in occupational health measures,
84 such as workplace environmental and health measures, have arisen and depend on the size of
85 the company. Such disparities have also been found in the establishment of COVID-19
86 countermeasures. Therefore, rather than the government's workplace vaccination program
87 ensuring vaccine equity, this program may have increased disparities in infection risk because
88 of differences in the completion of COVID-19 vaccination based on company size.

89 We conducted a prospective cohort study to examine the relationship between
90 company size and COVID-19 vaccination completion and the impact of the workplace
91 vaccination program on this relationship, focusing on the period between July and December

92 2021, when the general population in Japan was receiving the second vaccine dose.

93

94 **Methods**

95 **Study design and participants**

96 This study was a part of the Collaborative Online Research on Novel-coronavirus Work
97 Study (the CORoNa Work Study) and was conducted using a prospective cohort study design.
98 The survey was commissioned to the internet survey company Cross Marketing Inc. (Tokyo
99 Japan), and the data were collected using a self-administered online questionnaire. All
100 participants gave informed consent, and the study was approved by the ethics committee of
101 the University of Occupational and Environmental Health, Japan (approval number: R2-079
102 and R3-006).

103 The baseline survey was conducted from December 22 to 25, 2020. The protocol for
104 the baseline survey has been previously reported in detail [16]. The participants were aged
105 20–65 years and were employed at the time of the baseline survey (N=33,087). Participants
106 were included using cluster sampling by sex, age, region, and occupation. A total of 27,036
107 participants were included after excluding ineligible individuals: those for which no data on
108 company size was available, who worked in the medical or welfare sectors, or who were
109 older than 65 at the time of the follow-up survey.

110 The follow-up survey was conducted from December 15 to 22, 2021, 1 year after

111 baseline. A total of 18,560 participants responded to the survey. Among them, respondents
112 were excluded if they were unemployed, over 65 years of age, or employed in the health or
113 welfare sector and thus eligible for priority vaccination at the time of the follow-up survey.
114 Finally, 15,829 participants were included in the analysis. Figure 1 shows the flow diagram
115 for this study.

116

117 **Second COVID-19 vaccination dose status**

118 In the follow-up survey, we asked participants, “In what month did you receive the second
119 COVID-19 vaccination?” Participants were requested to choose one of 12 options: the
120 months of February 2021 through December 2021, or “have not received.” We then created a
121 variable for completion status for each month after July. For example, completion by the end
122 of September was defined as having received a second COVID-19 vaccine dose in any of the
123 months from February through September. If a participant received the second vaccine dose
124 in September, completion by July or August would be coded “no” but completion by
125 September, October, November, and December would be coded “yes”.

126

127 **Company size**

128 In the baseline survey, we asked participants, “How many employees are there at your
129 company?” The participants could choose one of 10 options: 1 person (self-employed) or 2–4,

130 5–9, 10–29, 30–49, 50–99, 100–499, 500–999, 1000–9999, or 10,000 or more persons. We
131 classified the responses into three categories: those who worked for small (1–49),
132 medium-sized (50–999), or large (1,000 or more) companies. This classification was made
133 because under the Industrial Safety and Health Act, the obligation to establish an
134 occupational health management system differs depending on the size of the worksite [17].
135 Furthermore, the government-provided workplace vaccination program was eligible for
136 locations that could vaccinate at least 1,000 people [13].

137

138 Company-arranged vaccination opportunity

139 In the follow-up survey, we asked participants, “Has your company arranged an opportunity
140 to receive the COVID-19 vaccine at the workplace, whether or not you took advantage of the
141 opportunity?” Participants could choose one of three response options: yes, no, or unknown.
142 We regarded “yes” to indicate that the vaccination opportunity was arranged, and the other
143 answers to indicate that this was not arranged.

144

145 Assessment of covariates

146 Participant characteristics were collected at baseline. The covariates included socioeconomic
147 factors, occupation, and industry. Age was classified into five groups: 20–29, 30–39, 40–49,
148 50–59, and 60–65 years. Annual household income was classified into five categories: <2.00

149 million Japanese yen (JPY), 2.00–3.99 million JPY, 4.00–5.99 million JPY, 6.00–7.99 million
150 JPY, and 8.00 million JPY or greater. Educational background was classified into three
151 categories: junior high or high school, vocational school or college, and university or
152 graduate school. Marital status was classified into three categories: married, divorced or
153 widowed, and unmarried. Occupation was classified into 10 categories: general employee;
154 manager; executive manager; public employee, faculty member, or non-profit organization
155 employee; temporary or contract employee; self-employed; small office/home office;
156 agriculture, forestry, or fishing; professional occupation (e.g., lawyer, tax accountant); and
157 other occupations. Participants could choose one of 22 options for their work industry, which
158 was then classified into nine categories based on the International Standard Industrial
159 Classification of All Economic Activities: manufacturing, public service, information and
160 communication, wholesale and retail, food service, education and religion, finance and
161 insurance, construction, and others.

162

163 **Statistical analysis**

164 The odds ratios (ORs) for the association between company size and completion of the
165 second COVID-19 vaccine dose were estimated using a multilevel logistic model nested in
166 the prefecture of residence to account for regional variability. The multivariate model was
167 adjusted for sex and age (Model 1) and additionally adjusted for annual household income,

168 educational background, marital status, occupation, and industry (Model 2). Finally, the
169 model was adjusted for company-arranged vaccination opportunity (Model 3).

170 A *p*-value of less than 0.05 was considered statistically significant. All analyses were
171 conducted using Stata (Stata Statistical Software: Release 16; StataCorp LLC, College
172 Station, TX, USA).

173

174 Results

175 Table 1 shows the participant characteristics by company size. Of the 15,829 participants,
176 4,272 (27%) worked for a large company, 5,117 (32%) for a medium-sized company, and
177 6,440 (41%) for a small company. As the company size increased, the percentage of
178 participants with a high annual household income and a high educational background level
179 increased. Furthermore, as the company size increased, the opportunity for
180 company-arranged vaccination increased: 56% for large companies, 35% for medium-sized
181 companies, and 14% for small companies.

182 <Insert Table 1>

183 Table 2 shows the ORs for the association between company size and completion of
184 the second COVID-19 dose by month. In the model adjusted only for age and sex (Model 1),
185 participants who worked for a medium-sized company were significantly less likely to
186 complete the second dose by August (OR=0.87, 95% CI: 0.79–0.94, *p*=0.001) and September

187 (OR=0.86, 95% CI: 0.78–0.93, $p<0.001$) than those who worked for a large company. For
188 small companies, the ORs decreased throughout the entire observation period, from July to
189 December. In the model adjusted for the main socioeconomic factors (Model 2), the ORs for
190 medium-sized and small companies tended to approach 1. For August and September, this
191 tendency remained, but no significant difference was observed for the medium-sized
192 companies. After adjusting for company-arranged vaccination opportunity (Model 3), the
193 significant difference between small and large companies disappeared for the entire period
194 analyzed. However, after October, participants who worked for medium-sized companies
195 were significantly more likely to have received the second vaccine dose than those who
196 worked for large companies (OR=1.14, 95% CI: 1.01–1.28, $p<0.029$). In each month
197 throughout the observation period, those who had a company-arranged vaccination
198 opportunity were significantly more likely to have received the second vaccine dose.

199 <Insert Table 2>

200

201 Discussion

202 This study showed that employees of smaller companies were less likely to have received a
203 second COVID-19 vaccine dose. In the months after the start of the workplace vaccination
204 program, the second dose completion rate of participants who worked for medium-sized
205 companies was lower than that of those who worked for large companies, but this difference

206 disappeared later in the observation period. The significant difference in completion rate
207 between small company employees and large company employees remained throughout the
208 observation period. The difference between large and medium-sized company employees
209 could mostly be explained by differences in socioeconomic factors. However, the difference
210 between the small and large company employees could not be explained by those factors
211 alone, although adjusting for the socioeconomic factors reduced the difference. After
212 adjusting for company-arranged vaccination opportunity, the difference in employee second
213 dose completion rate between large and small companies disappeared. Furthermore,
214 medium-size companies had higher vaccine completion coverage than large companies in the
215 latter half of the observation period.

216 The presence of vaccine hesitancy owing to a lack of trust in vaccination and other
217 factors has been a challenge to achieving herd immunity through vaccination. Socioeconomic
218 factors have been found to affect vaccination intention and uptake of other vaccines, such as
219 the seasonal influenza vaccine [18] and the H1N1 vaccine [19]. The effects of socioeconomic
220 factors on vaccination intention for the COVID-19 vaccine have also been examined [6,7].
221 Studies have generally found a positive association between vaccine uptake and annual
222 income and educational background, although some studies have shown inverse associations
223 [20, 21]. Several studies have found differences in willingness to vaccinate depending on
224 one's occupation and industry [22-24]. In the current study, after adjusting for socioeconomic

225 factors, the difference in vaccination completion rate among employees of medium and large
226 companies disappeared. After these adjustments, the difference between employees of small
227 and large companies also became smaller. These findings suggest that socioeconomic factors
228 affect the association between COVID-19 vaccination and company size in Japan.

229 In the present study, it was observed that participants who had a company-arranged
230 vaccination opportunity were significantly more likely to have received the second vaccine
231 dose, and after adjusting the model for the presence of a company-arranged vaccination
232 opportunity, no significant difference in the second dose completion rate was found between
233 employees of small and large companies for all months. These results suggests that the
234 government's implementation of the workplace vaccination program had a positive impact on
235 the vaccination acceptance of employees who worked for companies that participated in the
236 program. The company-arranged vaccination opportunities may have decreased vaccine
237 hesitancy and increased vaccination coverage. To evaluate the psychosocial factors
238 influencing vaccine hesitancy, in 2011, the WHO Strategic Advisory Group of Experts
239 proposed the "3C" model [4], which stands for "Confidence", "Convenience", and
240 "Complacency." German researchers subsequently proposed the "5C" model, substituting
241 "Constraints" for "Convenience" and adding "Calculation" and "Collective responsibility"
242 [25]. Company-arranged vaccination opportunities are thought to increase people's
243 confidence in a vaccine, and the availability of the vaccine at or near their workplace

244 increases its convenience. In addition, social environmental factors, such as social norms and
245 herding effects, have been suggested to affect one's vaccine intention [26,27]. The workplace
246 vaccination program facilitated employees' vaccination behavior to be shared among
247 coworkers and supervisors, which may have had a direct impact on the social norms and
248 herding effect. Previous studies on seasonal influenza vaccination in the U.S. have reported
249 that workplace vaccination practices and recommendations are associated with higher
250 vaccination coverage [28].

251 The influence of socioeconomic factors and company-arranged vaccination
252 opportunities on vaccination coverage has implications for the equitable allocation of
253 vaccines. In the workplace vaccination program, the government invited companies that
254 wished to implement the program on the premise that at least 1,000 people could be
255 vaccinated at a single location [13]. Multiple small companies could apply if they could
256 jointly secure more than 1,000 people willing to be vaccinated. However, because it was
257 necessary to arrange venues and medical personnel for the vaccination event and to
258 coordinate costs, program utilization may vary greatly depending on company size. In Japan,
259 employers with less than 50 full-time staff are not obligated to appoint an occupational health
260 physician or health supervisor or to establish a health committee. This lack of obligation
261 means that workers in small companies often do not have occupational health services
262 available to them [17]. In addition, during the COVID-19 pandemic in Japan, there were

263 marked differences among companies of different sizes in the implementation of remote work
264 and infection control measures [14,15]. The Japanese government's workplace vaccination
265 program may have contributed to health disparities. Therefore, the pros and cons of a
266 workplace vaccination program and the methods used to realize it warrant further discussion
267 to ensure a more equitable implementation in future infectious disease outbreaks.

268 It is unclear why there was significantly higher vaccination completion among
269 participants who worked for medium-sized companies compared with those who worked for
270 large companies after October 2021 in the model adjusted for both socioeconomic factors and
271 company-arranged vaccination opportunity. One possible explanation is that many employees
272 of large companies were located in offices other than the headquarters and therefore had
273 difficulty accessing the company-arranged vaccination opportunity. Another possibility is that,
274 although COVID-19 vaccination was voluntary, medium-sized companies are often in a
275 weaker business position than larger companies, and therefore they may have been more
276 influenced by pressure from clients to vaccinate their employees in order to continue doing
277 business.

278 This study had several limitations. First, the survey was conducted via the internet,
279 so generalizations should be made with caution. However, we attempted to reduce any bias
280 by using cluster sampling with stratification by sex, region, and job type. Second, the study
281 was likely affected by recall bias. The earlier vaccination was completed, the more time had

282 elapsed by the time of the survey, which may have caused recall bias. Third, the timing of the
283 follow-up survey might have affected the responses to the question of vaccination status in
284 the last month, December. If a person received their second vaccine dose in the last week of
285 December (after filling out the follow-up survey), they may have answered “unvaccinated”
286 when asked about their vaccination status in the follow-up survey. However, the impact of
287 this situation was likely small because second-dose vaccination was nearly complete in both
288 the community and workplace programs by the end of November, and less than 1% of the
289 respondents received their second vaccine dose in December.

290

291 Conclusion

292 During the period when COVID-19 vaccinations were being administered to the general
293 population in Japan, the coverage of receiving a second COVID-19 vaccine dose was
294 significantly lower for those who worked for small companies than for those who worked for
295 large companies. This difference could mostly be explained by socioeconomic factors and the
296 availability of a vaccination opportunity arranged by the employer. In the event of future
297 infectious disease outbreaks, it will be necessary to enhance support of vaccination for the
298 employees of small companies.

299

300 List of Abbreviations

301 COVID-19: coronavirus diseases 2019; mRNA: messenger RNA; WHO: World Health
302 Organization; JPN: Japanese yen; OR: odds ratio; CI: confidence interval.

303

304

305

References

- 306 1. Lu R, Zhao X, Li J, Niu P, Yang B, Peihua N, et al. Genomic characterisation and
307 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor
308 binding. *Lancet*. 2020;395:565–74. [https://doi.org/10.1016/S0140-6736\(20\)30251-83-16](https://doi.org/10.1016/S0140-6736(20)30251-83-16).
- 309 2. Conte C, Sogni F, Affanni P, Veronesi L, Argentiero A, Esposito S. Vaccines against
310 Coronaviruses: The State of the Art. *Vaccines*. 2020;8:309.
311 <https://doi.org/10.3390/vaccines8020309>
- 312 3. Jin Y, Hou C, Li Y, Zheng K, Wan C. mRNA Vaccine: How to Meet the Challenge of
313 SARS-CoV-2. *Front Immunol*. 2022;12:821538.
314 <https://doi.org/10.3389/fimmu.2021.821538>.
- 315 4. MacDonald NE, SAGE Working Group on Vaccine Hesitancy Vaccine. Vaccine
316 hesitancy: Definition, scope and determinants. *Vaccine*. 2015;33(34):4161-64.
317 <https://doi.org/10.1016/j.vaccine.2015.04.036>.
- 318 5. Larson JH, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine
319 hesitancy around vaccines and vaccination from a global perspective: a systematic review

- 320 of published literature, 2007-2012. *Vaccine*. 17;32(19):2150-59.
- 321 <https://doi.org/10.1016/j.vaccine.2014.01.081>.
- 322 6. Lazarus JV, Ratzan SC, Adam Palayew A et al. A global survey of potential acceptance of
- 323 a COVID-19 vaccine. 2021; 27(2):225-228. <https://doi.org/10.1038/s41591-020-1124-9>.
- 324 7. Sallam M. COVID-19 vaccine hesitancy worldwide: A concise systematic review of
- 325 vaccine acceptance rates. *Vaccines (Basel)* 2021; 9(2):160.
- 326 <https://doi.org/10.3390/vaccines9020160>.
- 327 8. National Academies of Sciences, Engineering, and Medicine; Health and Medicine
- 328 Division; Board on Population Health and Public Health Practice; Board on Health
- 329 Sciences Policy; Committee on Equitable Allocation of Vaccine for the Novel
- 330 Coronavirus. Framework for Equitable Allocation of COVID-19 Vaccine. National
- 331 Academies Press (US); 2020. <https://doi.org/10.17226/25917>
- 332 9. Okubo R, Yoshioka T, Ohfuji S, Matsuo T, Tabuchi T. COVID-19 Vaccine Hesitancy and
- 333 Its Associated Factors in Japan. *Vaccines (Basel)* 2021;9(6):662. [https://doi.org/](https://doi.org/10.3390/vaccines9060662)
- 334 [10.3390/vaccines9060662](https://doi.org/10.3390/vaccines9060662).
- 335 10. Ishimaru T, Okawara M, Ando H, Hino A, Nagata T, Tateishi S, et al. Gender differences
- 336 in the determinants of willingness to get the COVID-19 vaccine among the working-age
- 337 population in Japan. *Hum Vaccin Immunother*. 2021;17(11): 3975-81.
- 338 <https://doi.org/10.1080/21645515.2021.1947098>.

- 339 11. Prime Minister's Office of Japan. About inoculation schedule of COVID-19 vaccine [In
340 Japanese].https://www.kantei.go.jp/jp/headline/kansensho/vaccine_supply.html. Accessed
341 31 March, 2022.
- 342 12. Ministry of Health, Labour and Welfare. About inoculation to medical staff etc. [In
343 Japanese]. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_iryuujuujisha.html.
344 Accessed 31 March, 2022.
- 345 13. Ministry of Health, Labour and Welfare. Notice of inoculation at the workplace [In
346 Japanese]. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_shokuiki.html.
347 Accessed 31 March, 2022.
- 348 14. Ishimaru T, Nagata M, Hino A, Yamashita S, Tateishi S, Tsuji M. Workplace measures
349 against COVID-19 during the winter third wave in Japan: Company size-based
350 differences. *J Occup Health*. 2021;63(1):e12224.
351 [Hpps://doi.org/10.1002/1348-9585.12224](https://doi.org/10.1002/1348-9585.12224).
- 352 15. Sasaki N, Imamura K, Kataoka M, Kuroda R, Tsuno K, Sawada U, et al. COVID-19
353 measurements at the workplace in various industries and company sizes: a 2-month
354 follow-up cohort study of full-time employees in Japan. *Environ Occup Health Practice*.
355 2021;3. <https://doi.org/10.1539/eohp.2020-0017-OA>.
- 356 16. Fujino Y, Ishimaru T, Eguchi H, Tsuji M, Tateishi S, Ogami A, et al. Protocol for a
357 nationwide Internet-based health survey in workers during the COVID-19 pandemic in

- 358 2020. J UOEH 2021;43(2):217-25. <https://doi.org/10.7888/juoeh.43.217>.
- 359 17. Mori K. Current Status and Issues for the Role of Occupational Health Physicians in
360 Japan. 2018 JMA Journal. 1(1)15-21. <https://doi.org/10.31662/jmaj.2018-0011>
- 361 18. Schmid P, Rauber D, Betsch C, Lidolt G, Denker M-L. Barriers of Influenza Vaccination
362 Intention and Behavior – A Systematic Review of Influenza Vaccine Hesitancy, 2005 –
363 2016. PLoS One. 2017;12:e0170550. <https://doi.org/10.1371/journal.pone.0170550>.
- 364 19. Gargano LM, Painter JE, Sales JM, Morfaw C, Jones LM, Murray D, et al. Seasonal and
365 2009 H1N1 influenza vaccine uptake, predictors of vaccination and self-reported barriers
366 to vaccination among secondary school teachers and staff. Hum Vaccin. 2011; 7(1):89–95.
367 <https://doi.org/10.4161/hv.7.1.13460>.
- 368 20. Hak E, Schönbeck Y, De Melker H, Van Essen GA, Sanders EA. Negative attitude of
369 highly educated parents and health care workers towards future vaccinations in the Dutch
370 childhood vaccination program. Vaccine 2005; 23 (24): 3103-7. [https://doi.org/](https://doi.org/10.1016/j.vaccine.2005.01.074)
371 [10.1016/j.vaccine.2005.01.074](https://doi.org/10.1016/j.vaccine.2005.01.074).
- 372 21. Wei F, Mullooly JP, Goodman M, McCarty MC, Hanson AM, Crane B, et al.
373 Identification and characteristics of vaccine refusers. BMC Pediatr 2009; 9: 18.
374 [https://doi: 10.1186/1471-2431-9-18](https://doi.org/10.1186/1471-2431-9-18).
- 375 22. King WC, Rubinstein M, Reinhart A, Mejia R. COVID-19 vaccine hesitancy
376 January-May 2021 among 18-64 year old US adults by employment and occupation. Prev

- 377 Med Rep. 2021;24:101569. <https://doi.org/10.1016/j.pmedr.2021.101569>.
- 378 23. Wang K, Wong EL, Ho K, Cheung AW, Yau PS, Dong D, et al. Change of willingness to
379 accept COVID-19 vaccine and reasons of vaccine hesitancy of working people at
380 different waves of local epidemic in Hong Kong, China: Repeated cross-sectional surveys.
381 Vaccines (Basel). 2021;9(1):62. <https://doi.org/10.3390/vaccines9010062>.
- 382 24. Dorman C, Perera A, Condon C, Chau C, Qian J, Kalk K, et al. Factors associated with
383 willingness to be vaccinated against COVID-19 in a large convenience sample. J
384 Community Health. 2021;46(5):1013-19. <https://doi.org/10.1007/s10900-021-00987-0>.
- 385 25. Betsch C, Schmid P, Heinemeier D, Korn L, Holtmann C, Böhm R. Beyond confidence:
386 Development of a measure assessing the 5C psychological antecedents of vaccination.
387 PLoS One. 2018;13(12):e0208601. <https://doi.org/10.1371/journal.pone.0208601>.
- 388 26. Kang GJ, Culp RK, Abbas KM. Facilitators and barriers of parental attitudes and beliefs
389 toward school-located influenza vaccination in the United States: Systematic review.
390 Vaccine 2017;35(16):1987-95. <https://doi.org/10.1016/j.vaccine.2017.03.014>.
- 391 27. Agranov M, Elliott M, Ortoleva P. The importance of Social Norms against Strategic
392 Effects: The case of Covid-19 vaccine uptake. Econ Lett 2021;206:109979.
393 <https://doi.org/10.1016/j.econlet.2021.109979>.
- 394 28. Luz PM, Johnson RE, Brown HE. Workplace availability, risk group and perceived
395 barriers predictive of 2016-17 influenza vaccine uptake in the United States: A

396 cross-sectional study. Vaccine. 2017;35(43):5890-5896.

397 <https://doi.org/10.1016/j.vaccine.2017.08.078>.

398

399 **Figure title**

400 **Figure 1. Flow diagram of the study participants**

401

402 **Declarations**

403 **Ethical approval and consent to participate**

404 This study was approved by the ethics committee of the University of Occupational and
405 Environmental Health, Japan (reference nos. R2-079 and R3-006). Informed consent was
406 obtained from all participants via the survey website.

407

408 **Consent for publication**

409 Not applicable.

410

411 **Availability of data and material**

412 Data available on request from authors.

413 **Competing interests**

414 The authors declare that they have no competing interests.

415

416 **Funding**

417 The study was supported and partly funded by research grants from the University of
418 Occupational and Environmental Health, Japan (no grant number), the Japanese Ministry of
419 Health, Labour and Welfare (H30-josei-ippan-002, H30-roudou-ippan-007, 19JA1004,
420 20JA1006, 210301-1, and 20HB1004), Anshin Zaidan (no grant number), the Collabo-Health

421 Study Group (no grant number), Hitachi Systems, Ltd. (no grant number), and scholarship
422 donations from Chugai Pharmaceutical Co., Ltd. (no grant number). The funders were not
423 involved in the study design, collection, analysis, or interpretation of data, the writing of this
424 article, or the decision to submit it for publication.

425

426 Authors' contributions

427 KM designed the analysis, analyzed the data, and wrote the manuscript. TM designed the
428 analysis and reviewed the manuscript. TM created the questionnaire, advised on the study
429 design and data interpretation, and reviewed the manuscript. HA, AH, ST, MT, and SM
430 reviewed the manuscript and advised on the data interpretation. YF was chairperson of the
431 study group, created the questionnaire, advised on the data interpretation, and reviewed the
432 manuscript.

433

434 Acknowledgments

435 The current members of the CORoNa Work Study, in alphabetical order, are as follows: Dr. Hajime Ando,
436 Dr. Hisashi Eguchi, Dr. Yoshihisa Fujino (present chairperson of the study group), Dr. Arisa Harada, Dr.
437 Ayako Hino, Dr. Kazunori Ikegami, Dr. Tomohiro Ishimaru, Dr. Kyoko Kitagawa, Ms. Ning Liu, Dr.
438 Kosuke Mafune, Dr. Shinya Matsuda, Dr. Ryutaro Matsugaki, Dr. Koji Mori, Dr. Keiji Muramatsu, Dr.
439 Masako Nagata, Dr. Tomohisa Nagata, Dr. Akira Ogami, Dr. Makoto Okawara, Dr. Rie Tanaka, Dr.

440 Seiichiro Tateishi, Dr. Shinya Matsuda, Dr. Tomohiro Ishimaru, and Dr. Tomohisa Nagata. All members are
441 affiliated with the University of Occupational and Environmental Health, Japan. We also thank Katherine
442 Thieltges from Edanz (<https://jp.edanz.com/ac>) for editing a draft of this manuscript.
443

444 Table 1. Participant characteristics according to company size

	Size of belonging company (Number of employees)		
	Large (1000 or more)	Medium (50-999)	Small (1-49)
Total	4272	5117	6440
Age			
20-29	185 (4.3%)	259 (5.1%)	173 (2.7%)
30-39	611 (14.3%)	764 (14.9%)	769 (11.9%)
40-49	1222 (28.6%)	1601 (31.3%)	1898 (29.5%)
50-59	1755 (41.1%)	1929 (35.7%)	2511 (39.0%)
60-65	499 (11.7%)	664 (13.0%)	1089 (16.9%)
Sex			
Men	2781 (65.1%)	3172 (62.0%)	3785 (58.8%)
Women	1491 (34.9%)	1945 (38.0%)	2665 (41.2%)
Annual household income (million JPY)			
<2	128 (3.0)	226 (4.4%)	660 (10.3%)
≥2 and <4	514 (12.0%)	990 (19.3%)	1594 (24.8%)
≥4 and <6	828 (19.4%)	1316 (25.7%)	1610 (25.0%)
≥6 and <8	997 (23.3%)	1068 (20.9%)	1105 (17.2%)
≥8	1805 (42.3%)	1517 (29.6%)	1471 (22.8%)
Educational background			
Junior high or high school	1018 (23.8%)	1426 (27.9%)	2117 (32.9%)
Vocational school, junior college or technical school	613 (14.4%)	1003 (19.6%)	1575 (24.5%)
University or graduate school	2641 (61.8%)	2688 (52.5%)	2748 (42.7%)
Marital status			
Married	1244 (29.1%)	1704 (33.3%)	2296 (35.7%)
Widowed/divorced	339 (7.9%)	432 (8.4%)	755 (11.7%)
Never married	2689 (62.9%)	2981 (58.3%)	3389 (58.3%)
Occupation			
General employee	2104 (49.3%)	2773 (54.2%)	2423 (37.6%)
Manager	691 (16.2%)	753 (14.7%)	382 (5.9%)
Executive manager	31 (0.7%)	107 (2.1%)	494 (7.7%)
Public employee, faculty member, or non-profit organization employee	806 (18.9%)	606 (11.8%)	354 (5.5%)
Temporary/contract employee	603 (14.1%)	810 (15.8%)	340 (5.3%)
Independent business (commercial and industrial services)	9 (0.2%)	15 (0.3%)	1548 (24.0%)
Small office/home office	3 (0.1%)	3 (0.1%)	270 (4.2%)
Agricultural, forestry, and fishing industries	2 (0.0%)	3 (0.1%)	135 (2.1%)
Professional occupation (lawyer, tax accountant, etc.)	11 (0.3%)	14 (0.3%)	140 (2.2%)
Other occupation	12 (0.3%)	33 (0.6%)	354 (5.5%)
Industry			
Manufacturing	1069 (25.0%)	1179 (23.0%)	755 (11.7%)
Public service	638 (14.9%)	389 (7.6%)	203 (3.2%)
Information and technology	312 (7.3%)	331 (6.5%)	287 (4.5%)
Retail and wholesales	244 (5.7%)	355 (6.9%)	629 (9.8%)
Eating/drinking	110 (2.6%)	182 (3.6%)	513 (8.0%)
Education and religion	275 (6.4%)	417 (8.1%)	507 (7.9%)
Finance	434 (10.2%)	213 (4.2%)	161 (2.5%)
Construction	96 (2.3%)	139 (2.7%)	428 (6.7%)
Other	1064 (25.6%)	1912 (37.4%)	2957 (45.9%)
Vaccination arranged by company			
Yes	2383 (55.8%)	1780 (34.8%)	914 (14.2%)
No	1889 (44.2%)	3337 (65.2%)	5526 (85.8%)
Month of 2nd COVID-19 vaccination			
February-June	161 (3.0%)	205 (4.0%)	197 (3.1%)
July	450 (10.5%)	467 (9.1%)	607 (9.4%)
August	1267 (29.7%)	4354 (26.5%)	1550 (24.1%)
September	941 (22.0%)	1140 (22.3%)	1380 (21.4%)
October	774 (18.1%)	1063 (20.8%)	1212 (18.8%)
November	240 (5.6%)	319 (6.2%)	420 (6.5%)
December	21 (0.5%)	35 (0.7%)	40 (0.6%)
Non-vaccinated	418 (9.8%)	534 (10.4%)	1034 (16.1%)

445

446 Table 2 Association between company size and completion of the second COVID-19 vaccine dose

Second vaccination	model 1			model 2			model 3			
	Comp. size	OD	95%CI	P value	OD	95%CI	P value	OD	95%CI	P value
by July										
Large	Ref.				Ref.			Ref.		
Medium	0.93	0.82-1.05	0.229		0.98	0.86-1.10	0.691	1.06	0.94-1.21	0.330
Small	0.77	0.69-0.87	<0.001		0.79	0.69-0.90	0.002	0.94	0.82-1.07	0.350
Vaccination by comp.								1.56	1.40-1.74	<0.001
by August										
Large	Ref.				Ref.			Ref.		
Medium	0.87	0.79-0.94	0.001		0.92	0.84-1.00	0.065	1.05	0.96-1.15	0.277
Small	0.67	0.62-0.73	<0.001		0.76	0.69-0.83	<0.001	0.98	0.89-1.08	0.692
Vaccination by comp.								1.98	1.83-2.15	<0.001
by September										
Large	Ref.				Ref.			Ref.		
Medium	0.86	0.78-0.93	0.001		0.92	0.84-1.01	0.085	1.04	0.95-1.15	0.349
Small	0.64	0.59-0.70	<0.001		0.77	0.70-0.84	<0.001	0.97	0.88-1.07	0.541
Vaccination by comp.								1.90	1.76-2.07	<0.001
by October										
Large	Ref.				Ref.			Ref.		
Medium	0.92	0.82-1.02	0.127		1.00	0.89-1.12	0.971	1.14	1.01-1.28	0.029
Small	0.54	0.48-0.61	<0.001		0.75	0.67-0.84	<0.001	0.95	0.85-1.07	0.377
Vaccination by comp.								2.05	1.84-2.27	<0.001
by November										
Large	Ref.				Ref.			Ref.		
Medium	0.93	0.81-1.10	0.218		1.01	0.88-1.15	0.918	1.15	1.01-1.32	0.042
Small	0.54	0.48-0.61	<0.001		0.73	0.64-0.83	<0.001	0.94	0.82-1.08	0.362
Vaccination by comp.								2.14	1.88-2.43	<0.001
by December										
Large	Ref.				Ref.			Ref.		
Medium	0.94	0.82-1.07	0.329		1.02	0.89-1.17	0.759	1.17	1.02-1.35	0.029
Small	0.54	0.48-0.61	<0.001		0.73	0.64-0.83	<0.001	0.93	0.81-1.07	0.317
Vaccination by comp.								2.14	1.83-2.15	<0.001

447 model 1: adjusted for age and sex

448 model 2: model 1+ adjusted for annual household income, education, marital status, occupation and industry


449 model 3: model 2 + adjusted for company-arranged vaccination

450 Size of company: large (1-49); medium-sized (50-999); large (1000 or more)

451 Vaccination by comp.: vaccination arranged by company

452

453



454

455

456 Fig 1

457

458

459

460

461